The possibility that a disordered immune response is related to the development of the rheumatic diseases has been an attractive hypothesis for investigation for years. Several investigators have attempted to demonstrate quantitative differences in the immune response between patients with these diseases and control subjects when they were inoculated with various antigens. Rantz, Creger and Choy (1) challenged patients with rheumatic fever and rheumatoid arthritis by injecting isologous red blood cells intravenously, and by the inoculation of influenza A and B vaccine. The patients with rheumatic fever responded with an increased titer of isohemagglutinins and in increased titer of antibodies to influenza virus compared with the control groups. There was no difference in the immune response to these two antigens between the rheumatoid arthritic patients and control subjects. In a prospective study, Rejholec (2) administered brucella vaccine subcutaneously to a group of 900 children. A small group developed very high titers of brucella antibody, measured by the indirect Coombs technique. All the children were followed clinically and a very high percentage of the hyper-reactors were shown subsequently to develop rheumatic fever; indeed, the only cases of rheumatic fever appeared in this hyper-reactor group. Miller, Kibrick, and Massel (3), by using influenza virus and typhoid. 0 and H antigens, were unable to show hyperreactivity in a group of patients with rheumatic *
The possibility that a disordered immune response is related to the development of the rheumatic diseases has been an attractive hypothesis for investigation for years. Several investigators have attempted to demonstrate quantitative differences in the immune response between patients with these diseases and control subjects when they were inoculated with various antigens. Rantz, Creger and Choy (1) challenged patients with rheumatic fever and rheumatoid arthritis by injecting isologous red blood cells intravenously, and by the inoculation of influenza A and B vaccine. The patients with rheumatic fever responded with an increased titer of isohemagglutinins and in increased titer of antibodies to influenza virus compared with the control groups. There was no difference in the immune response to these two antigens between the rheumatoid arthritic patients and control subjects. In a prospective study, Rejholec (2) administered brucella vaccine subcutaneously to a group of 900 children. A small group developed very high titers of brucella antibody, measured by the indirect Coombs technique. All the children were followed clinically and a very high percentage of the hyper-reactors were shown subsequently to develop rheumatic fever; indeed, the only cases of rheumatic fever appeared in this hyper-reactor group. Miller, Kibrick, and Massel (3), by using influenza virus and typhoid. 0 Argentina. fever. Other studies with pneumococcal polysaccharide by Quinn, Seastone and Dickie (4) and with diphtheria toxoid by Kuhns and McCarty (5) similarly showed no hyper-reactivity.
The present studies were initiated in the face of these conflicting data and with the following two objectives in mind: 1) to determine whether differences in antibody response to an antigenic stimulus of a nonstreptococcal, presumably unfamiliar antigen could be demonstrated between control patients and patients with various rheumatic diseases; and 2) to determine whether challenge by a specific heterologous antigen might influence one or another of the abnormal antibodies or antibodylike substances circulating in the blood of patients with rheumatic diseases.
MATERIALS AND METHODS
Nineteen patients with rheumatoid arthritis in all stages of activity, 11 patients with systemic lupus erythematosus, 5 patients with acute rheumatic fever, and 6 patients with acute glomerulonephritis formed the study group.
Almost all patients with rheumatoid arthritis, rheumatic fever and systemic lupus erythrematosus were under chronic corticosteroid therapy. Twenty-seven patients with various nonrheumatic diseases (cerebral vascular accident, congestive heart failure, various neurological syndromes) served as hospitalized, chronically ill, control subjects. These control subjects were comparable in age, although predominantly male (Table I ). The patients with rheumatic diseases, as one might expect in rheumatoid arthritis and systemic lupus erythematosus, were predominantly female. Forty apparently normal subjects, the kindred of nonrheumatic patients, acted as normal ambulatory control subjects.
Each patient was inoculated subcutaneously with 0.5 ml of brucella vaccine (Parke-Davis) containing Brucella abortus and melitensis, 2,000 million killed bacteria per ml. In most cases, blood samples were obtained before inoculation and at 1, 2 and 3 weeks after inoculation. In 2 patients, samples were obtained at 2-day intervals. In 12 cases, samples were taken once a week for periods of months. In many instances the following agglutinations were performed on the several samples of a single patient simultaneously. Antibrucella agglutinins were measured by the slide agglutination technique, with diagnostic febrile antigen for brucella (Lederle), according to the method of Huddleson and Abell (6) . The sera of 2 control patients and 2 rheumatic patients were independently studied by Dr. D. Widelock of the Department of Health, New York City, and comparable titers of brucella antibodies were found. Isohemagglutinin titers were determined as described by Kabat (7) and antiglobulin tests were performed as described by Rosenfield, Vogel and Rosenthal (8) . Lupus erythematosus cell preparations were made in accordance with the method of Lee (9) , and antistreptolysin titers were done by the method of Rantz and Randall (10) .
Antinuclear antibody titers were performed by a fluorescent antibody technique described previously (11) Titers of all antibodies will be expressed as the reciprocal of the dilution. All of the antinuclear antibodies, lupus erythematosus preparations, and anti-thyroglobulin antibodies were done on all of the samples of each patient at the same time. Serum complement titrations were determined with slight modifications according to the technique described by Kabat and Mayer (13) . Paper electrophoresis was performed in a Durrum-type cell (Manual of Paper Electrophoresis, model R, Beckman Instrument Co., 1958). The absolute values of different fractions were determined as the percentage of total protein measured by the biuret method or by refractometry.
Sedimentation characteristics of the antibrucella agglutinins, the rheumatoid factor, and the antinuclear antibodies were studied in a Spinco model L ultracentrifuge by 2 different procedures. Initially, serum diluted in saline was centrifuged at 40,000 rpm in a 40.2 rotor for 1 to 2 hours; after centrifugation, serial aliquots of 8 successive layers were removed consecutively from the top to the bottom of the tube. Afterward, better results were obtained by means of the zone centrifugation technique. This was done with the swinging bucket SW 39 rotor, using a sucrose density gradient, as described by Kunkel (14) . groups at the 2-week interval shows that both the family control group and the hospitalized patient control group were significantly less reactive than the rheumatoid arthritis group 1 (Table II) . Because the sample number in the systemic lupus erythematosus group was 10, the p value is not significant, but the difference between groups would be significant if the sample were larger. Brucella antigen had been chosen for these experiments because it was presumed that it had not been met by the subjects and hence was satisfactory for stimulation. The possibility exists that for some of our patients the antigen was not unfamiliar. Of the total of 68 patients inoculated, three had positive antibrucella agglutinin titers before inoculation. These three, with titers of 20, 40, and 80 were in the systemic lupus erythematosus group. The mean titer at 2 weeks in the rheumatoid arthritis group was 555 and in the systemic lupus erythematosus group was 400. The small size of the rheumatic fever and glo- (Table III) . Isohemagglutinin titers, antinuclear antibodies, complement levels and total serum y-globulin did not show appreciable change in these patients following brucella antigen stimulation. In 4 of the 11 patients in this group, however, transiently positive direct antiglobulin tests were observed during the peak immune response to brucella. In five patients with systemic lupus erythematosus, serial blood samples were examined for antibodies to various influenza viruses 2 (Table IV) . Four of these patients showed patterns in their influenza antibodies which are not unusual for their age group in New York City; these patterns did not change during the immunization period. In one patient, however, there was an initial titer of 64 for the FM 1 strain. Two weeks after a subcutaneous injection of 0.1 ml of brucella antigen, this titer rose to 512, although titers to all of the other strains tested remained zero. It is possible that this patient had an infection with the FM 1 virus during this period, although this virus has not been isolated in New York City in recent years.
RESULTS

A. Brucella antibodies
Anti-thyroglobulin antibodies were detected before immunization in two patients in titers of 4 and 64 (Table III) . Two weeks after stimulation these antibodies were detected in three additional patients in titers of 2, 8 and 16, although the original two patients did not have any subsequent change in their titers.
Rheumatoid arthritis. Titers of isohemagglutinins and serum y-globulin showed no significant change. One patient developed a positive Coombs test 8 weeks after brucella inoculation.
In seven patients of this group serial determinations of the latex particle fixation were made. In three of these seven there was significant parallel rise of latex particle fixation titer as the brucella agglutinin titer rose (Figure 3. ).
Since it is well known that the disulfide bridge of the macroglobulins can be disrupted by the addition of sulfhydryl-containing compounds with subsequent loss of antibody activity, mercaptoethanol was added to seven high-titer brucella and latex sera in 0.01 M concentration. There resulted a marked loss of agglutinating activity of both the brucella and latex system. Ultracentrifugation of these sera revealed that both the brucella agglutinins and the latex particle fixation activity resided in the 19S component and that the 7S component was inactive in both systems. Similarly, the brucella agglutinins resided in the 19S fraction of the control sera (Tables V and VI) .
In order to differentiate clearly both 19S activities, the same seven test sera (with both a high titer of brucella antibodies and a high titer in the latex particle fixation) were repeatedly absorbed with brucella antigen until no brucella antibodies could be demonstrated. After absorption these sera still had their initial activity in the latex particle fixation system. patient with rheumatoid arthritis, of 15 tested, had detectable anti-thyroglobulin antibody. Approximately 2 weeks after inoculation these antibodies were detected in five patients in titers of 1, 1, 32, 2 and 2 (Table VII) . Control group. No latex particle fixation activity or lupus erythematosus cell factor was found in the initial serum of any of the control group. In the initial sera of 16 patients, no anti-thyroglobulin antibody was noted. In 13 of these patients no anti-thy-roglobulin activity was found after inoculation with brucella antigen and during the period of brucella agglutinin response; y-globulin in the control patients did not vary in the serial samples.
DISCUSSION
In this series of experiments, there were statistical differences in antibody response between the rheumatic disease patients and the control patients after brucella stimulation. The agglutination reaction used to detect the antibrucella agglutinins was specific. Parallel agglutinations using Sal-demonstrated to be separate from rheumatoid facmonella typhosa were uniformly negative. Anti-tor. Further, rheumatoid factor had no enhancing brucella agglutinins in systemic lupus erythemato-effect when added to low-titer antibrucella sera. sus patients were distinct from antinuclear anti-
The possibility that the agglutinating phenomebodies, and in rheumatoid arthritis patients were non was related nonspecifically to the presence of Of all the other antibodies studied, only four appeared to increase in titer secondarily to stimulation by brucella antigen. Four of 11 patients with systemic lupus erythematosus showed transiently positive direct antiglobulin (Coombs) tests; 1 of 5 systemic lupus erythematosus patients showed a marked rise in titer of an unusual influenza antibody (FM 1); and 3 of 7 rheumatoid arthritis patients showed possible (and 3 others showed suggestive) rises in latex particle fixation titer, admittedly a crude measure of rheumatoid factor. Anti-thyroglobulin antibodies occurred after brucella inoculation in 3 of 11 patients with systemic lupus erythematosus, and in 5 of 15 patients with rheumatoid arthritis. In all these instances the antibody activities measured were actually separate from the brucella agglutinins.
In all instances, when positive, the Coombs test became positive 2 to 8 weeks after stimulation; in two instances, the presence of an anti-red cell factor paralleled a sudden increase in titer of brucella agglutinins. The very high titer against influenza antibody occurred 2 weeks after a second dose of 0.1 ml of brucella vaccine.
Detectable anti-thyroglobulin antibody occurred in titers of 16, 2 and 8 in the systemic lupus erythematosus patients after inoculation. In two of the patients (J.H. and R.W.) anti-red cell antibody was transiently present at the same time. In the third patient (J.E.) the unusual titer to F.M 1 strain of influenza virus, previously alluded to, had occurred. Two systemic lupus erythematosus patients had anti-thyroglobulin antibody before brucella inoculation; these showed no increase in their titer of anti-thyroglobulin antibody.
Prior to stimulation, no patient with rheumatoid arthritis had detectable anti-thyroglobulin antibody; 2 weeks later, 5 of 15 patients tested had detectable antibody. One of these 5 patients developed a titer of 32 at the same time that she developed an increase in the latex particle fixation titer from 160 to 5,120.
Thus, of a total of 11 antibody activities studied in rheumatic disease patients after brucella inoculation, significant alterations (appearance de novo or definite increase of titer) were observed in 4. These alterations occurred in 7 of 19 patients with rheumatoid arthritis and in 5 of 11 patients with systemic lupus erythematosus. Among the rheumatic disease subjects exhibiting this type of reactivity, there was a tendency for multiple changes in individual patients. Four patients with systemic lupus erythematosus and one with rheumatoid arthritis showed alterations in two different antibody activities (anti-red cell plus anti-thyroglobulin in three patients, anti-red cell plus anti-influenza in one patient, and rheumatoid factor plus anti-thyroglobulin in one).
The significance of this broad spectrum of antibody response to a single antigenic stimulus is obscure. All rheumatic disease subjects did not show this phenomenon, but it seems likely that if more antibody activities had been measured, more reactive patients would have been found. It is possible, too, that the pattern which appears heresingle antigenic stimulus yielding broad scattering of antibody response-may provide a basis for understanding the wide range of abnormal antibody activities found in systemic lupus erythematosus and rheumatoid arthritis. Autoimmunity has been thought to require some alteration of a normal tissue component to create antigenicity of this tissue (15) or the sudden availability of a normal tissue component for the immune system (16) . The present results could be interpreted as indicating that the altered host response may be a basic defect in some "autoimmune" diseases.
There is some support for the hypothesis that this altered immune response may be genetically determined. This possibility has been suggested by the findings of serological and clinical abnormalities in the kindred of patients with systemic lupus erythematosus and rheumatoid arthritis (17) (18) (19) (20) .
In these studies no control patient showed response to brucella inoculation in any antibody activity other than that directed specifically against brucella; this lends support to the suggested hypothesis of Antibodies may be classified by their electrophoretic and sedimentation characteristics into three groups: y-2 (7S), -y-1-M (or ,8-2-M) (19S), and /8-2-A. Attempts are now being made to define the antibodies studied according to this classification. The antibrucella agglutinins in the present series have been shown to belong to the y-1-M group, as does the rheumatoid factor. It seems possible that this approach may be a fruitful one and that all the "responding" antibodies may belong to this class. Studies are now under way to stimulate antibodies of another class in similar patients. SUMMARY 1. Forty-one patients with various rheumatic diseases and 27 control patients were inoculated with brucella vaccine. As a group the patients exhibited a significantly greater rise in antibrucella agglutinins compared with the controls. Some overlap in both groups was present.
2. Alterations were noted in other antibody systems-anti-red cell (Coombs), anti-thyroglobulin, and possibly in the influenza antibody and rheumatoid factor-after this primary stimulation in some of the patients with rheumatic diseases, but no titers for these antibodies were noted in the control patients.
3. The effect of brucella antigen in these patients may be related to the damage that this organism can produce on mesenchymal tissue.
